Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
5mg |
|
||
10mg |
|
||
Other Sizes |
|
Purity: ≥98%
ln Vitro |
On 4T1 breast cancer cells and 4306 ovarian cancer cells, PI-828 (0.01-100 μM) has cytotoxic effects [2]. Higher quantities of PI-828 alone (6.25-12.5 µM) induce apoptosis, while PI-828 (0.78-3.12 µM; 48 hours) decreases caspase 3 activation [3].
|
---|---|
Cell Assay |
Cell viability assay [2]
Cell Types: 4T1 breast cancer cells and 4306 ovarian cancer cells Tested Concentrations: 0.01, 0.1, 1, 10 and 100 μM Incubation Duration: Experimental Results: demonstrated cytotoxic effect. Apoptosis analysis[3] Cell Types: Human Embryonic Carcinoma NCCIT Cell Tested Concentrations: 0.78, 1.56, 3.12, 6.25, 12.5 μM Incubation Duration: 48 hrs (hours) Experimental Results: 0.78 to 3.12 μM Concentration range reduces caspase 3 activation; higher concentrations cause Apoptosis. |
References |
[1]. Gharbi SI, et al. Exploring the specificity of the PI3K family inhibitor LY294002. Biochem J. 2007 May 15;404(1):15-21.
[2]. Kulkarni AA, et al. Supramolecular nanoparticles that target phosphoinositide-3-kinase overcome insulin resistance and exert pronounced antitumor efficacy. Cancer Res. 2013 Dec 1;73(23):6987-97. [3]. Zellefrow CD, et al. Identification of druggable targets for radiation mitigation using a small interfering RNA screening assay. Radiat Res. 2012 Sep;178(3):150-9. |
Molecular Formula |
C19H18N2O3
|
---|---|
Molecular Weight |
322.35782
|
CAS # |
942289-87-4
|
SMILES |
O=C1C=C(N2CCOCC2)OC3=C(C4=CC=C(N)C=C4)C=CC=C13
|
InChi Key |
WUKMIBOGGXMBAC-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C19H18N2O3/c20-14-6-4-13(5-7-14)15-2-1-3-16-17(22)12-18(24-19(15)16)21-8-10-23-11-9-21/h1-7,12H,8-11,20H2
|
Chemical Name |
8-(4-aminophenyl)-2-(4-morpholinyl)-4H-1-benzopyran-4-one
|
Synonyms |
PI-828; PI 828; PI828
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ≥ 12.5 mg/mL (~38.78 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (3.88 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (3.88 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.1021 mL | 15.5106 mL | 31.0212 mL | |
5 mM | 0.6204 mL | 3.1021 mL | 6.2042 mL | |
10 mM | 0.3102 mL | 1.5511 mL | 3.1021 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.